Literature DB >> 34687846

Cas12a variants designed for lower genome-wide off-target effect through stringent PAM recognition.

Jin Zhou1, Peng Chen1, Hongjian Wang1, Huan Liu1, Yongzheng Li1, Youpeng Zhang1, Yankang Wu1, Chonil Paek1, Zaiqiao Sun1, Jun Lei2, Lei Yin3.   

Abstract

Cas12a is an RNA-guided endonuclease that has been widely used for convenient multiplex gene editing with low off-target effects. To minimize off-targeting in gene editing, we engineered a variant of LbCas12a (termed Lb-K538R) with more stringent PAM recognition, lower off-targeting capability, and similar editing efficiency in vivo compared with LbCas12a. We also demonstrated that Lb2Cas12a from Lachnospiraceae bacterium MA2020 has extensive gene-editing activities in mammalian cells. Similar to Lb-K538R, the designed Lb2Cas12a variant (termed Lb2-K518R) not only had a more stringent PAM sequence change from YYN to TYN (Y is T or C, N is A, T, C, or G), but also displayed lower off-target effects, thereby enabling more potential target site selections with low off-targeting than the common TTTV (V is A, G, or C) PAM. To determine whether this type of mutation at the homologous position had similar effects in other Cas12a, As-K548R was evaluated. Based on the results of the genome-wide off-target test, As-K548R displayed lower off-target effects. Collectively, our findings indicate that the Cas proteins could be designed to be stringent in PAM recognition to reduce their off-target effects, which suggests a promising and practical approach for minimizing off-targets effects in genome editing.
Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR; Lb-K538R; Lb2-K518R; PAM stringency; off-targeting

Mesh:

Substances:

Year:  2021        PMID: 34687846      PMCID: PMC8753454          DOI: 10.1016/j.ymthe.2021.10.010

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  41 in total

1.  Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease.

Authors:  Cem Kuscu; Sevki Arslan; Ritambhara Singh; Jeremy Thorpe; Mazhar Adli
Journal:  Nat Biotechnol       Date:  2014-05-18       Impact factor: 54.908

Review 2.  Applications of CRISPR-Cas in agriculture and plant biotechnology.

Authors:  Haocheng Zhu; Chao Li; Caixia Gao
Journal:  Nat Rev Mol Cell Biol       Date:  2020-09-24       Impact factor: 94.444

Review 3.  Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants.

Authors:  Kira S Makarova; Yuri I Wolf; Jaime Iranzo; Sergey A Shmakov; Omer S Alkhnbashi; Stan J J Brouns; Emmanuelle Charpentier; David Cheng; Daniel H Haft; Philippe Horvath; Sylvain Moineau; Francisco J M Mojica; David Scott; Shiraz A Shah; Virginijus Siksnys; Michael P Terns; Česlovas Venclovas; Malcolm F White; Alexander F Yakunin; Winston Yan; Feng Zhang; Roger A Garrett; Rolf Backofen; John van der Oost; Rodolphe Barrangou; Eugene V Koonin
Journal:  Nat Rev Microbiol       Date:  2019-12-19       Impact factor: 60.633

4.  FLASH assembly of TALENs for high-throughput genome editing.

Authors:  Deepak Reyon; Shengdar Q Tsai; Cyd Khayter; Jennifer A Foden; Jeffry D Sander; J Keith Joung
Journal:  Nat Biotechnol       Date:  2012-05       Impact factor: 54.908

5.  GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.

Authors:  Shengdar Q Tsai; Zongli Zheng; Nhu T Nguyen; Matthew Liebers; Ved V Topkar; Vishal Thapar; Nicolas Wyvekens; Cyd Khayter; A John Iafrate; Long P Le; Martin J Aryee; J Keith Joung
Journal:  Nat Biotechnol       Date:  2014-12-16       Impact factor: 54.908

6.  Cpf1 nucleases demonstrate robust activity to induce DNA modification by exploiting homology directed repair pathways in mammalian cells.

Authors:  Eszter Tóth; Nóra Weinhardt; Petra Bencsura; Krisztina Huszár; Péter I Kulcsár; András Tálas; Elfrieda Fodor; Ervin Welker
Journal:  Biol Direct       Date:  2016-09-14       Impact factor: 4.540

7.  Engineered Cpf1 variants with altered PAM specificities.

Authors:  Linyi Gao; David B T Cox; Winston X Yan; John C Manteiga; Martin W Schneider; Takashi Yamano; Hiroshi Nishimasu; Osamu Nureki; Nicola Crosetto; Feng Zhang
Journal:  Nat Biotechnol       Date:  2017-06-05       Impact factor: 54.908

8.  Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells.

Authors:  Benjamin P Kleinstiver; Shengdar Q Tsai; Michelle S Prew; Nhu T Nguyen; Moira M Welch; Jose M Lopez; Zachary R McCaw; Martin J Aryee; J Keith Joung
Journal:  Nat Biotechnol       Date:  2016-06-27       Impact factor: 54.908

9.  A Cas12a ortholog with stringent PAM recognition followed by low off-target editing rates for genome editing.

Authors:  Peng Chen; Jin Zhou; Yibin Wan; Huan Liu; Yongzheng Li; Zhaoxin Liu; Hongjian Wang; Jun Lei; Kai Zhao; Yiliang Zhang; Yan Wang; Xinghua Zhang; Lei Yin
Journal:  Genome Biol       Date:  2020-03-25       Impact factor: 13.583

Review 10.  The promise and challenge of therapeutic genome editing.

Authors:  Jennifer A Doudna
Journal:  Nature       Date:  2020-02-12       Impact factor: 49.962

View more
  1 in total

1.  Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity.

Authors:  Hongxin Huang; Guanjie Huang; Zhihong Tan; Yongfei Hu; Lin Shan; Jiajian Zhou; Xin Zhang; Shufeng Ma; Weiqi Lv; Tao Huang; Yuchen Liu; Dong Wang; Xiaoyang Zhao; Ying Lin; Zhili Rong
Journal:  BMC Biol       Date:  2022-04-25       Impact factor: 7.364

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.